Williams Eugene

Director Williams Eugene purchased 2,000 shares of PMN at $24.40 on 2026-03-05, expanding holdings to 12,397 shares.

Williams Eugene, a director of ProMIS Neurosciences, purchased 2,000 shares at $24.40, increasing his stake by 19.2% to 12,397 shares. The transaction occurred after three consecutive open-market buys on 2026-03-02, 2026-03-03, and 2026-03-04—a concentrated buying pattern over four consecutive trading days. The stock now trades at $23.40, down 16.4% from its 52-week high of $28.00 despite a 49.5% gain over the preceding 30 days. Against this backdrop of fundamental headwinds—the company is unprofitable with net income of $-11,580,126.00 and a P/E ratio of 212.73—the director's rapid accumulation suggests a conviction in near-term upside, though prior same-ticker outcomes are not yet measurable.

Director Williams Eugene bought 4,000 PMN shares across 3 trades (Mar 2-4) for $92,420.00 at blended avg $23.10

Williams Eugene, a director of ProMIS Neurosciences, completed 3 separate purchases totaling 4,000 shares for $92,420.00 between March 2 and March 4, 2026, increasing his holdings by 62.5% from 6,397 to 10,397 shares. The transactions occurred at prices ranging from $21.89 to $24.00, within 14.1% of the current $24.05 price, and notably during a period of significant price momentum: the stock has risen 71.2% over 30 days and 215.2% over 90 days from a 52-week low of $6.76. The timing occurs in a company context marked by net losses of $-11,580,126.00 and an elevated P/E of 218.64, creating a backdrop where insider accumulation suggests conviction independent of traditional valuation metrics. The substantial share increase during strong upward momentum warrants examination of the underlying strategic or operational drivers supporting this accumulation.